Overview

A Trial to Evaluate the Safety Tolerability and Pharmacokinetics of B1344 by Subcutaneous Injection in Healthy Subjects

Status:
Recruiting
Trial end date:
2024-01-30
Target enrollment:
Participant gender:
Summary
To evaluate the safety, tolerability, and immunogenicity of B1344 by single subcutaneous (s.c.) injection in healthy subjects
Phase:
Phase 1
Details
Lead Sponsor:
Tasly Biopharmaceuticals Co., Ltd.
Treatments:
Mitogens